Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TYR | P14679 | 1/20 | 0.35 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13339153 | 0.74 | KDM4E (0.63) | TYRDOHHKDM4E | |
| SCHEMBL9813218 | 0.65 | SMN1; SMN2 (0.39) | SMN1; SMN2 | |
| SCHEMBL17233963 | 0.65 | — | — | |
| SCHEMBL666590 | 0.64 | — | — | |
| SCHEMBL9813226 | 0.64 | SMN1; SMN2 (0.38) | SMN1; SMN2 | |
| SCHEMBL4602946 | 0.62 | CA12 (0.51) | SMN1; SMN2TYRDOHHKDM4E | |
| SCHEMBL6302015 | 0.61 | NPC1 (0.42) | SMN1; SMN2KDM4E | |
| SCHEMBL4375225 | 0.61 | CA12 (0.47) | SMN1; SMN2KDM4E | |
| SCHEMBL276358 | 0.61 | SMN1; SMN2 (0.39) | SMN1; SMN2 | |
| SCHEMBL9602409 | 0.59 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7919521-B2 | Five-membered iminocyclitol derivatives as selective and potent glycosidase inhibitors: new structures for antivirals and osteoarthritis therapeutics | ACADEMIA SINICA (TW) | 2011-04-05 | — | — | US | disclosed |
| US-20090306174-A1 | Novel Five-Membered Iminocyclitol Derivatives as Selective and Potent Glycosidase Inhibitors: New Structures for Antivirals and Osteoarthritis Therapeutics | ACADEMIA SINICA (TW) | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306174-A1 | Novel Five-Membered Iminocyclitol Derivatives as Selective and Potent Glycosidase Inhibitors: New Structures for Antivirals and Osteoarthritis Therapeutics | ACE2, ENGASE, DPP7 | SMN1; SMN2 239/4885TYR 2094/4885DOHH 704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.